Effective February 2, 2015 the Quebec Ministry of Health advised that a best lowest price policy will apply for Infliximab and its indications (what diseases it is approved to treat). This means that all prescriptions for the originator drug Remicade will be substituted with the Subsequent Entry Biologic, Inflectra, which is approximately 30% cheaper than Remicade. If a patient and their doctor opt for Remicade, the patient has to make up the approximately $8,000 difference.
However, it appears that exceptions can be made. The doctor can write “Do not substitute prescription” on prescriptions to patients currently on Remicade or who do not live near an Inflectra infusion location. In these cases the full cost of the Remicade will be covered.